Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Agenus (Nasdaq: AGEN) reported Phase 2 data for botensilimab (BOT) plus balstilimab (BAL) in advanced checkpoint-refractory cutaneous melanoma (36 patients) to be presented at ASCO 2026.
Median overall survival was 16.6 months, 2‑year survival 42%, and median duration of response was not reached, with 86% of responders in response at 12 months.
Agenus (Nasdaq: AGEN) reported retrospective ASCO 2026 data using Noetik’s AI TARIO-2 platform to analyze routine pretreatment H&E tumor images from 113 patients treated with botensilimab (BOT) plus balstilimab (BAL).
In refractory MSS metastatic colorectal cancer without active liver metastases, an AI-identified subgroup showed a 64% response rate to BOT+BAL versus 9% in the remaining cohort, and significantly better overall survival, with median OS not reached and a hazard ratio of 0.18. TARIO-2 outperformed benchmark pathology foundation models and may support future image-based biomarker strategies for BOT+BAL, subject to prospective validation.
Agenus (Nasdaq: AGEN) reported Phase 1b data for botensilimab + balstilimab in treatment-refractory hepatocellular carcinoma after prior immunotherapy, published in Liver Cancer. The 19-patient cohort included 47% with ALBI grade 2 liver function.
Among 18 efficacy-evaluable patients, the combination showed a 17% ORR (one complete, two partial responses), 50% 18-week CBR, median PFS of 4.4 months, and median OS of 12.3 months. Safety was described as manageable, with no treatment-related deaths and no grade 4 or higher immune-mediated adverse events.
Agenus (Nasdaq: AGEN) reported Q1 2026 results and key BOT+BAL milestones. Total revenue was $33.7M (vs $24.1M Q1 2025), with net income of $39.2M (vs $(26.4)M loss). Cash was $35.0M at March 31, 2026.
BOT+BAL advanced into Phase 3 BATTMAN enrollment, authorized access expanded globally, and the $91M Zydus collaboration closed, adding capital and U.S. manufacturing capacity. The SEC investigation concluded with no enforcement action, and a related securities class action was dismissed.
Agenus (Nasdaq: AGEN) will release its first quarter 2026 financial results before the market opens on May 11, 2026.
The company plans a June webcast tied to its Annual Meeting to review strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development programs.
Agenus (NASDAQ: AGEN) will present four abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, 2026) covering botensilimab (BOT) alone and with balstilimab (BAL) across advanced cutaneous melanoma, colorectal cancer, and translational biomarker research.
The program includes the first Phase 2 melanoma data presentation, an AI biomarker poster, and two colorectal cancer trial updates with scheduled poster times and presenters noted.
Agenus (Nasdaq: AGEN) appointed BAP Pharma as its exclusive global partner to coordinate access programs for botensilimab plus balstilimab (BOT+BAL).
BAP Pharma will manage France's government-reimbursed AAC pathway, paid named-patient programs in select countries, logistics, case coordination and payment processing. Agenus reported >270 physician inquiries from >30 countries and cites ongoing Phase 3 BATTMAN development.
Agenus (NASDAQ: AGEN) reported Phase II investigator-initiated data showing a 77% disease control rate (DCR) and long-term survival beyond 20 months in a subset of heavily pretreated PD-1 refractory gastroesophageal cancer patients.
Patients receiving an induction strategy had longer PFS (6.9 vs. 3.5 months; HR 0.19; p=0.015) and longer median OS (9.5 vs. 5.2 months), with 43% of induction-treated patients alive at 12 and 18 months. The study did not meet its primary ORR endpoint; safety was consistent with component agents.
Agenus (Nasdaq: AGEN) will present investigator‑initiated Phase II data of a novel triplet immunotherapy—botensilimab (BOT) + balstilimab (BAL) with agenT‑797—in PD‑1 refractory gastroesophageal cancer (GEC) at AACR 2026.
Presentation is April 20, 2026 (2:00–5:00 PM PT / 5:00–8:00 PM EDT), Poster Section 52, Abstract CT166. Data aim to inform immune modulation, sequencing, and durability of response in checkpoint‑refractory tumors.
Agenus (Nasdaq: AGEN) announced enrollment of the first patient in the global Phase 3 BATTMAN (CO.33) trial (NCT07152821) testing botensilimab (BOT) + balstilimab (BAL) versus best supportive care in refractory, unresectable MSS/pMMR metastatic colorectal cancer.
The registrational study plans to enroll approximately 830 patients across >100 sites in Canada, France, Australia and New Zealand through cooperative groups CCTG, GI Cancer Trials and PRODIGE.